Welcome to our dedicated page for Beta Bionics news (Ticker: BBNX), a resource for investors and traders seeking the latest updates and insights on Beta Bionics stock.
Beta Bionics reports developments for a commercial-stage medical device company focused on diabetes management for insulin-requiring people. Its core product, the iLet Bionic Pancreas, uses adaptive closed-loop algorithms and is an FDA-cleared insulin delivery device that autonomously determines insulin doses.
Company news commonly covers quarterly financial results and guidance, net sales through Durable Medical Equipment and Pharmacy Benefit Plan channels, new patient starts, product software such as Bionic Insights within Bionic Reports, and diabetes-technology development programs including the Mint patch pump and bihormonal system.
Beta Bionics (Nasdaq: BBNX), a leader in advanced diabetes management solutions, has appointed Gerard Michel as an independent board director effective March 26, 2025. Michel, currently CEO of Delcath Systems (Nasdaq: DCTH), brings over 30 years of pharmaceutical and medical technology industry experience.
Michel's extensive background includes serving as CFO at Vericel , CFO and VP of Corporate Development at Biodel Inc. (2007-2014), and similar roles at NPS Pharmaceuticals (2002-2007). He previously held positions at Booz Allen and worked in commercial roles at Lederle Labs and Wyeth Labs.
Michel holds an M.S. in Microbiology from the University of Rochester School of Medicine, an M.B.A. from Simon School of Business, and dual B.S. degrees in Biology and Geology.
Beta Bionics (NASDAQ: BBNX) reported strong Q4 and full-year 2024 financial results. Q4 net sales reached $20.4M, up 145% YoY, with DME channel sales of $18.1M (+127%) and PBP channel sales of $2.4M (+491%). The installed customer base grew to 15,298 users (+564%).
Full-year 2024 showed net sales of $65.1M (+443% YoY), with DME channel sales of $58.8M and PBP channel sales of $6.3M. The company completed an IPO raising $206M and launched the Color iLet Bionic Pancreas with FreeStyle Libre 3 Plus integration.
For 2025 guidance, Beta Bionics expects revenue of $80-85M, with over 20% of new patient starts through PBP channel and gross margin of at least 50%. The company ended 2024 with $103.6M in cash and equivalents.
Beta Bionics (NASDAQ: BBNX), a leader in advanced diabetes management solutions, has scheduled the release of its Q4 and full year 2024 financial results for March 25, 2025, after market close.
The company will host a conference call and webcast at 4:30 PM ET (1:30 PM PT) on the same day to discuss the financial performance. Investors can access the webcast through the company's investor relations website, and a replay will be available afterward.
Beta Bionics (Nasdaq: BBNX) has successfully completed its upsized initial public offering, raising $234.6 million. The company sold 13,800,000 shares of common stock at $17.00 per share, including the full exercise of the underwriters' option for 1,800,000 additional shares. The IPO generated approximately $212.1 million in gross proceeds for Beta Bionics before expenses.
Additionally, the company conducted a concurrent private placement of 1,000,000 shares at the IPO price to an existing investor, bringing total gross proceeds to approximately $229.1 million. Trading began on the Nasdaq Global Market on January 30, 2025, under the ticker symbol 'BBNX'. The offering was led by BofA Securities, Piper Sandler, and Leerink Partners as lead bookrunners, with Stifel as bookrunner and Lake Street Capital Markets as co-manager.
Beta Bionics has announced the pricing of its upsized initial public offering of 12,000,000 shares of common stock at $17.00 per share, expecting to raise gross proceeds of $204.0 million. The company's shares will begin trading on the Nasdaq Global Market on January 30, 2025, under the ticker symbol BBNX.
The underwriters have a 30-day option to purchase up to an additional 1,800,000 shares. Additionally, Beta Bionics has agreed to sell 1,000,000 shares in a concurrent private placement at the same price, bringing the total potential gross proceeds to $221.0 million before expenses.
The offering is expected to close on January 31, 2025. BofA Securities, Piper Sandler, and Leerink Partners are acting as lead bookrunners, with Stifel as bookrunner and Lake Street Capital Markets as co-manager.